Related Experiment Video
Updated: Jul 4, 2026
14:39
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
Long-acting beta(2) agonists in asthma and allergic rhinitis
Maria Gabriella Matera1, Giacomo Curradi, Mario Cazzola
12nd University of Naples, Department of Experimental Medicine, Naples, Italy.
Expert Opinion on Pharmacotherapy
|June 4, 2008
Summary
Long-acting beta(2) agonists (LABAs) show potential in asthma but require further study for allergic rhinitis. More research is needed to understand their role and potential synergy with other treatments in upper airway diseases.
Area of Science:
- Respiratory Medicine
- Pharmacology
- Allergy and Immunology
Background:
- Long-acting beta(2) agonists (LABAs) are established second-line asthma controllers.
- LABAs may increase risks in specific asthma scenarios.
- The link between asthma and allergic rhinitis is well-documented, yet LABA efficacy in rhinitis is unclear.
Purpose of the Study:
- To review the role of beta(2) agonists in asthma patients with co-existing allergic rhinitis.
- To elucidate the differing effects of short-acting (SABAs) and long-acting beta(2) agonists (LABAs) on allergic rhinitis.
Main Methods:
- Comprehensive literature search of SCOPUS, Google Scholar, and MEDLINE databases.
- Search conducted in March 2008 with no language restrictions.
- Review of abstracts and published papers.
Main Results:
- Existing studies present conflicting findings regarding LABA use in allergic rhinitis.
- The "united airway" concept suggests shared therapeutic pathways for asthma and rhinitis.
- Data on SABAs in rhinitis is more established than for LABAs.
Conclusions:
- Further well-designed studies on LABAs in allergic rhinitis are essential.
- Investigating the anti-inflammatory synergy between inhaled corticosteroids and LABAs in the upper airways is crucial.
- Ultra-LABAs (once-daily) appear unlikely to be effective in allergic rhinitis based on current information.
Related Concept Videos
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
01:17Drugs Used in Lower Respiratory Disorders: Overview
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:30Asthma-IV: Diagnostic and Management
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:30Adrenergic Agonists: Therapeutic Uses
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...